Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using 82Rb PET/CT

2018 ◽  
Vol 27 (6) ◽  
pp. 2048-2059 ◽  
Author(s):  
Jonathan T. Abele ◽  
Monique Raubenheimer ◽  
Vincent G. Bain ◽  
Greg Wandzilak ◽  
Naji AlHulaimi ◽  
...  
Keyword(s):  
Blood Flow ◽  
Liver Disease ◽  
Dobutamine Stress ◽  
End Stage Liver Disease ◽  
Pet Ct ◽  
End Stage ◽  
Blood Flow Evaluation

scholarly journals P1552 Dobutamine stress echocardiography as a screening tool for coronary artery disease detection in patients with end-stage liver disease awaiting transplantation

2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
C Masoura ◽  
M Bonou ◽  
C Kapelios ◽  
D Dambasis ◽  
M Skouloudi ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Liver Transplantation ◽  
Liver Disease ◽  
Cardiovascular Events ◽  
Stress Echocardiography ◽  
Dobutamine Stress Echocardiography ◽  
Dobutamine Stress ◽  
End Stage Liver Disease ◽  
Artery Disease ◽  
End Stage

Abstract Indroduction The prevalence of coronary artery disease (CAD) in patients with end-stage liver disease (ESLD) is unknown. However, patients with CAD and ESLD are at increased perioperative risk during liver transplantation. Currently there is no standard protocol for CAD screening in patients with ESLD awaiting orthotopic liver transplantation. We present preliminary data of our experience with dobutamine stress echocardiography in those patients. Methods Fifty patients (26 males, mean age of 59 years) with end-stage liver disease awaiting transplantation and no history of CAD underwent dobutamine stress echo. The etiology of their hepatic disease was hepatitis B (6 patients), hepatitis C (6 patients), primary billiary cirrhosis (10 patients), sclerosing cholangitis (8 patients), alcoholic hepatitis (10 patients) and polycystic disease (2 patients), while 8 patients had end-stage liver disease of unknown etiology. Twenty-six patients had risk factors for CAD. Eighteen patients had one risk factor and only 8 patients had 2 risk CAD factors. All patients received dobutamine infusion (at escalating doses of 5, 10, 20, 30 and 40 μgr/kg/min), targeting a 85% or more of their age-predicted maximum heart rate. Atropine was administered in 6 patients. Results All 50 patients had normal inotropic response of left ventricle, without evidence of ischemia (100% studies were negative for ischaemia). No patient had major intolerance to dobutamine. Eight patients experienced hypotension responded to infusion of normal saline. One patient developed paroxysmal supraventricular tachycardia, which was treated with intravenous bolus of adenosine. No patient had cardiovascular events during a follow-up ranging from 1 to 18 months. Twelve patients underwent liver transplantation without any periprocedural cardiovascular events. Conclusions Dobutamine stress echocardiography is a safe and reliable method for CAD screening in the labile patients with ESLD who are candidates for orthotopic liver transplantation. It seems that the prevalence of significant CAD in this high-risk population is low.

scholarly journals Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease

2019 ◽  
Vol 12 (11) ◽  
pp. 2115-2122 ◽  
Author(s):  
Anisiia T. Doytchinova ◽  
Thomas D. Feigenbaum ◽  
Roja C. Pondicherry-Harish ◽  
Peter Sepanski ◽  
Deborah Green-Hess ◽  
...  
Keyword(s):  
Liver Disease ◽  
Diagnostic Performance ◽  
Stress Echocardiography ◽  
Dobutamine Stress Echocardiography ◽  
Dobutamine Stress ◽  
End Stage Liver Disease ◽  
End Stage

scholarly journals Predictive Value of Dobutamine Stress Perfusion Echocardiography in Contemporary End‐Stage Liver Disease

2017 ◽  
Vol 6 (2) ◽  
Author(s):  
Bipul Baibhav ◽  
Chetaj A. Mahabir ◽  
Feng Xie ◽  
Valerie K. Shostrom ◽  
Timothy M. McCashland ◽  
...  
Keyword(s):  
Liver Disease ◽  
Predictive Value ◽  
Dobutamine Stress ◽  
Stress Perfusion ◽  
End Stage Liver Disease ◽  
End Stage

Position Paper on Treatment of Hepatitis C in Romania, 2017. Part One

2017 ◽  
Vol 26 (2) ◽  
pp. 171-181 ◽  
Author(s):  
Liana Gheorghe ◽  
Ioan Sporea ◽  
Speranţa Iacob ◽  
Roxana Şirli ◽  
Anca Trifan ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Limit Of Detection ◽  
Position Paper ◽  
Hcv Infection ◽  
Fixed Dose ◽  
Diagnostic Tools ◽  
End Stage Liver Disease ◽  
End Stage

Background & Aims: Hepatitis C Virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania, the mean prevalence is about 3%. New treatments became available on the market in recent years and new drugs are in the pipeline. A re-evaluation of HCV therapy was considered mandatory. The Romanian Society of Gastroenterology and Hepatology undertook this task for the practitioners of this country.Methodology: A group of recognized experts was created who screened the available literature and the major available guidelines. A list of items requiring attention has been created. These items were discussed and rated. Decisions were taken by consensus.Recommendations: We present here the first of the two parts of our Society’s recommendations for chronic HCV infection treatment. An agreement was reached regarding the diagnostic tools, the assessment of severity and the up-dated therapy schedules.Conclusions: This Position Paper represents a guide for the assessment and the therapy of HCV infection. The recommendations are in concordance with other guidelines but are applied to the real-life conditions in this country.Abbreviations: DAAs: Direct-acting antivirals; DDIs: Drug-drug interactions; ESLD: End-stage liver disease; ESRD: End-stage renal disease; eGFR: Estimated glomerular filtration rate; EASL: European Association for the Study of the Liver; EMA: European Medicines Agency; FDA: US Food and Drug Administration; FDC: Fixed-dose combination; GT: Genotype; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; LT: Liver transplantation; LLD: Lower limit of detection; MELD score: Mayo-Clinic End-Stage Liver Disease score; ANMDM: National Agency of Medicines and Medical Devices; PPIs: Proton pump inhibitors; PWID: People who inject drugs; RCT: Randomized controlled trial; RDT: Rapid diagnostic test; RAS: Resistance-associated substitution; SRGH: Romanian Society of Gastroenterology and Hepatology; SAE: serious adverse events; SPC: Summary of Product Characteristics; SVR: Sustained virologic response.

Sign in / Sign up

Export Citation Format

Share Document